Lexaria Bioscience (LEXX) 10-Q2021 Q3 Quarterly report

Filed: 15 Jul 21, 5:21pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: advance, allocated, alter, anomaly, assigned, ceased, charity, constant, CSE, delisting, Deposit, Description, diminished, donated, Downey, Employment, error, eventually, evolving, expenditure, field, fluctuate, force, foreseeable, Greg, Gregory, headquartered, India, investigatory, Japan, July, located, low, mathematical, milestone, practical, preliminary, promotion, rapidly, relax, requested, rotational, Security, situation, skew, staggered, team, titled, trial, ultimately, undertook, upcoming, voluntary, website

Removed: acceptable, Account, administration, aggressively, Allan, ancillary, applicability, assist, BC, built, CAD, carry, CDN, CEBA, certainty, choose, close, collaboration, collected, comparing, comply, conduct, constituted, contract, contractual, controlled, converted, cultivation, customer, default, difficult, directly, director, disease, dismissal, diversity, Emergency, emerging, encountering, enhancement, enhancing, environment, environmentally, estrogen, ethical, exact, excluded, experience, exploratory, extend, failing, federally, formed, geographic, government, governmental, growth, half, implemented, improve, increasingly, indirectly, insensitive, intend, introduce, investigating, involvement, loan, locally, maintained, manufacture, maximize, monitoring, month, operate, oral, outcome, pain, pertain, pilot, predicted, preserve, processing, prosecuted, protracted, publicity, quarantine, realization, recession, released, repaid, retain, safety, satisfaction, September, service, smoking, Spissinger, studied, study, submitted, suffer, suffered, superior, supply, sustainable, termination, testosterone, tightly, treat, turbulence, unethical, unique, university, USA, utilization, viewed, waiting, withstand, world

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

LEXX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Chris Bunka, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

	(1)	the Quarterly Report on Form 10-Q of Lexaria Bioscience Corp. for the quarter ended May 31, 2021 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

	(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Lexaria Bioscience Corp.

Dated: July 15, 2021

		/s/ “ Chris Bunka “
		Chris Bunka
		CEO and Director
		(Principal Executive Officer)
		Lexaria Bioscience Corp.

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Lexaria Bioscience Corp. and will be retained by Lexaria Bioscience Corp. and furnished to the Securities and Exchange Commission or its staff upon request.

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.